An article in Forbes reports on new findings that show ImClone Systems' colon cancer drug Erbitux and a similar drug from Amgen, Vectibix, may not work in half of colon cancer patients. By using a genetic test, it can tell patients whether they have tumors with a mutation in kras that would make the drugs ineffective.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.